Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of GSK933776 SC/IM vs IV in Healthy Volunteers
NCT02033668Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2014
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GSK933776 in geographic atrophy (GA) (4 arms), sponsored by GSK. Primary endpoints: Relative bioavailability of GSK933776 after single dose SQ or IM administration as compared to IV infusion and Relative bioavailability of GSK933776 after repeat dose SQ administration as compared to IV infusion. Started Jan 2014; status: completed.
02
Drugs
GSK933776
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02033668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02033668.